相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
Michaela J. Higgins et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Statin use and risk of breast cancer: a meta-analysis of observational studies
Krishna Undela et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Martin Thurnher et al.
CLINICAL CANCER RESEARCH (2012)
Statin Use and Reduced Cancer-Related Mortality
Sune F. Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
Jonathan R. Emberson et al.
PLOS ONE (2012)
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
Quinci Romero et al.
BMC CANCER (2011)
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Thomas P. Ahern et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
Donal J. Brennan et al.
BREAST CANCER RESEARCH (2011)
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
Elisabeth R. Garwood et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Molecular mechanisms involved in farnesol-induced apoptosis
Joung Hyuck Joo et al.
CANCER LETTERS (2010)
IL-2 Costimulation Enables Statin-Mediated Activation of Human NK Cells, Preferentially through a Mechanism Involving CD56+ Dendritic Cells
Georg Gruenbacher et al.
CANCER RESEARCH (2010)
Dysregulation of the mevalonate pathway promotes transformation
James W. Clendening et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users
Anjali S. Kumar et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors
Signe Borgquist et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
Signe Borgquist et al.
BREAST CANCER RESEARCH (2008)
Statin use and breast cancer risk in a large population-based setting
Denise M. Boudreau et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Breast cancer growth prevention by statins
Michael J. Campbell et al.
CANCER RESEARCH (2006)
Statin use and breast cancer: Prospective results from the Women's Health Initiative
JA Cauley et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Statins and cancer risk - A meta-analysis
KM Dale et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies
S Bonovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin
RE Duncan et al.
CANCER LETTERS (2005)
The risk of cancer in users of statins
MR Graaf et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clinical pharmacokinetics of atorvastatin
H Lennernas
CLINICAL PHARMACOKINETICS (2003)
Correlation between MIB-1 and other proliferation markers -: Clinical implications of the MIB-1 cutoff value
F Spyratos et al.
CANCER (2002)
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
U Laufs et al.
STROKE (2000)
分享论文
